Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study

April 23, 2011 at 3:48 pm Leave a comment

Journal of Antimicrobial Chemotherapy April 2011 V.66  N.suppl 3

Ronald N. Jones*, David J. Farrell, Rodrigo E. Mendes and Helio S. Sader

JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA



To document the spectrum of activity of ceftaroline, the active form of the prodrug, ceftaroline fosamil, a new cephalosporin with anti-methicillin-resistant staphylococcal activity, against a surveillance collection of clinical isolates obtained from theUSAandEuropeduring 2008–09.


A selected group of species associated with community-acquired pneumonia (CAP; 6496 of 17 326 monitored strains) were tested for susceptibility in a central laboratory using CLSI broth microdilution methods. Organisms were sampled from 55 medical centres,27 intheUSAand 28 (12 countries) inEurope. Ceftaroline and comparator agents were tested and interpretations of MIC endpoints made by applying current CLSI (2010) and EUCAST (2010) breakpoint criteria.


Against 1340 Streptococcus pneumoniae, ceftaroline inhibited all isolates at ≤0.5 mg/L (MIC50/90, ≤0.008/0.12 mg/L) and was 8-fold more active than ceftriaxone (MIC90, 1 mg/L; only 79.2% coverage at EUCAST breakpoint). Haemophilus influenzae (n = 584; MIC50/90, ≤0.008/0.015 mg/L), Moraxella catarrhalis (n = 377; MIC50/90, 0.03–0.06/0.12 mg/L) and Staphylococcus aureus (n = 590; MIC50/90, 0.5/1 mg/L) were very susceptible to ceftaroline, regardless of β-lactamase production or multidrug resistance (MDR) patterns. The potency of ceftaroline against three species of Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae) was similar to that of ceftriaxone, ceftazidime and piperacillin/tazobactam. Only modest differences in rates of ceftaroline susceptibility (breakpoint ≤2 mg/L) were noted with extended-spectrum β-lactamase-negative Enterobacteriaceae strains between theUSAandEurope(97.9% versus 97.0% for E. coli). Ceftaroline, like ceftriaxone, was not active against ceftazidime-resistant E. coli (10.2%–26.2% susceptible at ≤2 mg/L) or K. pneumoniae (5.3%–11.2%).


The ceftaroline surveillance for 2008–09 (USAandEurope) documented low MIC50/90 values for S. aureus isolates at 0.5/1 and 0.25/1 mg/L, respectively. More importantly, ceftaroline MIC90 results for S. pneumoniae (0.12 mg/L), H. influenzae (0.015 mg/L) and M. catarrhalis (0.12 mg/L) were very low, all MICs being ≤0.5 mg/L. Ceftaroline exhibited promising high potency and wide coverage against Gram-positive and -negative pathogens known to cause CAP, especially isolates of MDR pneumococci and methicillin-resistant S. aureus.



Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Infecciones respiratorias.

A Randomized Factorial Trial Comparing 4 Treatment Regimens in Treatment-Naive HIV-Infected Persons with AIDS and/or a CD4 Cell Count <200 Cells/µL in South Africa What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


April 2011

Most Recent Posts

%d bloggers like this: